✦ LIBER ✦

A 10-year postmarketing surveillance registry of adalimumab for moderate to severe psoriasis: Third-year interim results of ESPRIT

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A 10-year postmarketing surveillance reg

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 50 KB

ESPRIT: Interim results from a 10-year p

📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

ESPRIT: Year to year safety over 4 years

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Fourth-year interim safety and patient o

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Final results from OBSERVE-5, a 5-year o

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Long-term efficacy and safety of adalimu

✍ Kenneth Gordon; Kim Papp; Yves Poulin; Yihua Gu; Stephen Rozzo; Eric H. Sasso 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 347 KB